Onchocerciasis is a parasitic disease that is the second most common cause of infectious blindness in the world, affecting 25 million people, mostly in sub-saharan Africa. Mass drug administration (MDA) with ivermectin has been the mainstay of a successful international effort to reduce the burden of vision loss. Despite improvements in infection rates and blindness through MDA with ivermectin, adult worms are not killed or permanently sterilized by this drug and can live for greater than 10 years. Therefore, new treatments for onchocerciasis are critical to accelerating the rate of elimination of this blinding disease. Here we discuss an ongoing study of a new treatment for onchocerciasis.

Original languageEnglish
Pages (from-to)55-59
Number of pages5
JournalMissouri Medicine
Issue number1
StatePublished - Jan 1 2022


Dive into the research topics of 'New Research Aims to Optimize Therapy Against Onchocerciasis'. Together they form a unique fingerprint.

Cite this